Adaptimmune Therapeutics (FRA:473A) Cyclically Adjusted Book per Share: €1.72 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:473A Adaptimmune Therapeutics PLC FRA:473A
16 GF Score
Price €0.16
View Full Analysis

What is Adaptimmune Therapeutics Cyclically Adjusted Book per Share?

Adaptimmune Therapeutics FRA:473A 16 Cyclically Adjusted Book per Share is €1.72 as of Jun. 2025. GuruFocus rates FRA:473A with a GF Score™ of 16/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Adaptimmune Therapeutics's adjusted book value per share for the three months ended in Jun. 2025 was €-0.232. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.72 for the trailing ten years ended in Jun. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-26), Adaptimmune Therapeutics's current stock price is €0.162. Adaptimmune Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2025 was €1.72. Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio of today is 0.09.


Adaptimmune Therapeutics  (FRA:473A) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.162/1.72
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Adaptimmune Therapeutics Cyclically Adjusted Book per Share Related Terms


Adaptimmune Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Cyclically Adjusted Book per Share Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.57 2.11

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 2.07 2.11 1.68 1.72

FRA:473A vs BCLI, APRE, JSPR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:473A
16GF Score
Adaptimmune Therapeutics PLC FRA:473A
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptimmune Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adaptimmune Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2025 was:

Adj_Book= Book Value per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=-0.232/138.4000*138.4000
=-0.232

Current CPI (Jun. 2025) = 138.4000.

Adaptimmune Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201509 3.155 100.200 4.358
201512 3.048 100.400 4.202
201603 2.778 100.400 3.829
201606 2.477 101.000 3.394
201609 2.266 101.500 3.090
201612 2.225 102.200 3.013
201703 2.252 102.700 3.035
201706 2.184 103.500 2.920
201709 2.051 104.300 2.722
201712 1.831 105.000 2.413
201803 1.648 105.100 2.170
201806 1.497 105.900 1.956
201809 2.264 106.600 2.939
201812 2.075 107.100 2.681
201903 1.856 107.000 2.401
201906 1.574 107.900 2.019
201909 1.275 108.400 1.628
201912 1.058 108.500 1.350
202003 1.294 108.600 1.649
202006 2.341 108.800 2.978
202009 2.064 109.200 2.616
202012 1.812 109.400 2.292
202103 1.670 109.700 2.107
202106 1.478 111.400 1.836
202109 1.312 112.400 1.615
202112 1.167 114.700 1.408
202203 0.945 116.500 1.123
202206 0.825 120.500 0.948
202209 0.699 122.300 0.791
202212 0.470 125.300 0.519
202303 0.473 126.800 0.516
202306 0.519 129.400 0.555
202309 0.364 130.100 0.387
202312 0.159 130.500 0.169
202403 0.088 131.600 0.093
202406 0.350 133.000 0.364
202409 0.282 133.500 0.292
202412 0.044 135.100 0.045
202503 -0.134 136.100 -0.136
202506 -0.232 138.400 -0.232

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.72 mean?
Adaptimmune Therapeutics (FRA:473A) has a Cyclically Adjusted Book per Share of €1.72 as of Jun. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Cyclically Adjusted Book per Share too high?
Adaptimmune Therapeutics' current Cyclically Adjusted Book per Share is €1.72. Overall, Adaptimmune Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adaptimmune Therapeutics' Cyclically Adjusted Book per Share compare to BCLI and APRE?
Adaptimmune Therapeutics' Cyclically Adjusted Book per Share of €1.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Cyclically Adjusted Book per Share is €1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (FRA:473A) has a current Cyclically Adjusted Book per Share of €1.72. The current Cyclically Adjusted Book per Share is €1.72. Adaptimmune Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Adaptimmune Therapeutics (FRA:473A), the current Cyclically Adjusted Book per Share is €1.72 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges ADAPY:USA473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
16GF Score

Get the complete analysis for FRA:473A

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price